AnaptysBio (NASDAQ:ANAB) CEO Sells $1,089,203.19 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 17,679 shares of the company’s stock in a transaction on Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the sale, the chief executive officer owned 495,965 shares of the company’s stock, valued at $30,556,403.65. The trade was a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Daniel Faga also recently made the following trade(s):

• On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The shares were sold at an average price of $44.71, for a total value of $638,503.51.
• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The stock was sold at an average price of $45.11, for a total value of $415,102.22.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Stock Down 3.5%

NASDAQ:ANAB opened at $55.39 on Tuesday. The stock’s 50-day simple moving average is $55.49 and its 200 day simple moving average is $44.01. The firm has a market capitalization of $1.59 billion, a PE ratio of -106.52 and a beta of 0.32. AnaptysBio, Inc. has a twelve month low of $15.40 and a twelve month high of $68.39.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has authorized a share repurchase plan on Friday, March 27th that authorizes the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. grew its stake in shares of AnaptysBio by 2,236.6% in the third quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company’s stock worth $5,920,000 after purchasing an additional 185,053 shares during the last quarter. Panagora Asset Management Inc. bought a new position in AnaptysBio during the 2nd quarter worth $741,000. Assenagon Asset Management S.A. raised its position in AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the last quarter. 683 Capital Management LLC lifted its holdings in AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after buying an additional 304,373 shares during the period. Finally, XTX Topco Ltd acquired a new position in AnaptysBio during the 2nd quarter worth about $680,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ANAB shares. Stifel Nicolaus upped their price objective on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Barclays boosted their target price on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. Truist Financial upgraded shares of AnaptysBio to a “hold” rating in a report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Finally, Wedbush raised their price objective on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.44.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.